
Shares of Nektar Therapeutics (NASDAQ:NKTR) rose sharply in today's pre-market trading after the company announced it will release top-line data from the 16-week induction period in the ongoing global Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin on June 24, 2025.
Nektar Therapeutics shares jumped 30.3% to $12.44 in the pre-market trading session.